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Polypharmacology plays an important role in defining response and adverse effects of drugs. For some 
mechanisms, experimentally mapping polypharmacology is commonplace, although this is typically 
done within the same protein class. Four PARP inhibitors have been approved by the FDA as cancer 
therapeutics, yet a precise mechanistic rationale to guide clinicians on which to choose for a particular 
patient is lacking. The four drugs have largely similar PARP family inhibition profiles, but several 
differences at the molecular and clinical level have been reported that remain poorly understood. Here, 
we report the first comprehensive characterization of the off-target kinase landscape of four FDA-
approved PARP drugs. We demonstrate that all four PARP inhibitors have a unique polypharmacological 
profile across the kinome. Niraparib and rucaparib inhibit DYRK1s, CDK16 and PIM3 at clinically 
achievable, submicromolar concentrations. These kinases represent the most potently inhibited off-
targets of PARP inhibitors identified to date and should be investigated further to clarify their potential 
implications for efficacy and safety in the clinic. Moreover, broad kinome profiling is recommended for 
the development of PARP inhibitors as PARP-kinase polypharmacology could potentially be exploited 
to modulate efficacy and side-effect profiles.
It is now widely accepted that drugs often bind several proteins beyond their intended target (polypharmacol-
ogy), which has implications for both therapeutic efficacy and adverse-effects. Accordingly, there is an increasing 
interest in medicinal chemistry to rationally design multi-target compounds1–6. In addition, understanding of 
polypharmacology can lead to the exploitation of drugs in novel indications, such as the recent approval of crizo-
tinib in ROS1-driven non small cell lung cancer3,7,8. In this context, experimental and computational methods are 
increasingly being used to uncover previously unknown off-targets of drugs3,9–12.
The demonstration that BRCA1 and BRCA2 mutant human cancer cell lines and tumour xenografts are 
exquisitely sensitive to small-molecule inhibitors of poly (ADP-ribose) polymerase (PARP) was critical for the 
clinical development and approval of PARP inhibitors as single agents and provided the first clinical exempli-
fication of synthetic lethality in oncology13,14. All FDA-approved PARP inhibitors bind to the nicotinamide 
binding pocket of PARPs through a shared benzamide pharmacophore that is essential for PARP binding, 
but the individual agents differ in size and flexibility (Fig. 1a)15. In 2014, olaparib was the first PARP inhibi-
tor to be approved by the FDA for advanced BRCA-mutated ovarian cancer, followed by rucaparib which was 
licensed for the same indication in 2016 (https://www.fda.gov/drugs/resources-information-approved-drugs/
hematologyoncology-cancer-approvals-safety-notifications)16,17. Niraparib was then approved in 2017 as main-
tenance treatment for recurrent fallopian tube, ovarian and primary peritoneal cancers (Table 1)18. In 2018, olap-
arib and rucaparib also gained approval as maintenance treatment in the same types of cancer while olaparib was 
additionally licensed for BRCA-mutated HER2-negative breast cancer (Table 1)16–18. Most recently, talazoparib 
was approved for BRCA-mutated HER2-negative breast cancer19 (Table 1). Further PARP inhibitors, including 
veliparib, are under clinical development13,20,21. No strong rationale currently exists for selecting one PARP drug 
over the others in terms of clinical effectiveness and toxicity and prescription is largely based on the approved 
indication for each drug as well as the reimbursement policy of the relevant healthcare provider22,23. Deeper 
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understanding of the activity and liabilities of individual PARP inhibitors is therefore important to aid clinical 
decisions and benefit cancer patients as well as to guide the design of future PARP inhibitors.
Several differences between individual PARP inhibitors have already been reported at the cellular and clinical 
levels. When used at micromolar concentrations, differences in DNA strand break repair, phosphorylation of 
several proteins, cell cycle arrest, and anti-proliferative activities have been described between olaparib, ruca-
parib and veliparib in cancer cell lines24,25. Moreover, the different capacity of PARP inhibitors to trap PARP at 
the DNA damage site is widely accepted as important for the action of PARP inhibitors. Yet, the exact molecular 
mechanism of this is not completely understood26. Differences in cancer cell sensitivity and synthetic lethality 
also emerge from recent large-scale profiling experiments, in some instances leading to the prediction of distinct 
predictive genomic biomarkers (Supplementary Table 1)27,28. Overall, it seems important to investigate further the 
differences between PARP inhibitors and to explore the potential impact on clinical use.
The selectivity and polypharmacology of PARP inhibitors within the PARP-family was recently characterised 
in vitro using an enzymatic inhibition assay29. Of the four approved PARP inhibitors, niraparib was shown to 
be more selective for PARP1 and PARP2 compared to olaparib, rucaparib and talazoparib which show broader 
pan-PARP activity (Fig. 1b)29. However, this differential intra-family PARP selectivity is insufficient to explain all 
the differences observed between clinical PARP inhibitors. In 2014, we reported for the first time that the different 
polypharmacology patterns between PARP inhibitors extended beyond the PARP enzyme family30. We demon-
strated that rucaparib inhibited at least nine kinases with micromolar affinity whereas veliparib inhibited only 
two kinases and olaparib did not exhibit activity against any of the 16 kinases tested30. From a high-throughput 
screen for RPS6KB1 kinase inhibitors, we identified a series of carboxamidobenzimidazoles that were confirmed 
to bind RPS6KB1 by orthogonal methods including X-ray crystallography31. The carboxamidobenzimidazoles 
are known inhibitors of PARP32 and the existence of a crystal structure of a carboxamidobenzimidazole bound to 
RPS6KB1 kinase31 prompted our speculation that all PARP inhibitors could have an intrinsic capacity to inhibit 
kinases. This capacity could result from the ability of their shared benzamide pharmacophore to interact with the 
highly-conserved kinase hinge region (Fig. 1a)30,31. Accordingly, depending on its individual molecular size and 
decoration, each PARP inhibitor could have a unique off-target kinase profile that may remain as yet unexplored 
and would be important to characterise4,30.
More recently, an unbiased, large scale, mass spectrometry-based chemical proteomics approach uncovered new, 
low-potency affinities of the PARP inhibitor niraparib33. However, the chemical proteomics approach used was not able 
to reproduce published, stronger off-target kinase interactions30. This illustrates the limitations of any single method for 
identifying drug polypharmacology and indicates the need for a more comprehensive analysis30.
Figure 1. Chemical structures and known PARP activities of FDA-approved PARP inhibitors. (a) Chemical 
structures of the four FDA-approved PARP drugs. The benzamide core pharmacophore shared by all clinical 
PARP inhibitors is highlighted in bold with orange shading. The rest of the chemical structure that is not shared 
between the inhibitors and confers them with different size and flexibility has grey shading. (b) Known target 
profile of clinical PARP inhibitors across members of the PARP enzyme family. IC50 values are obtained from 
the literature and the ChEMBL database (www.ebi.ac.uk/chembl/) and ranges are given where there is more 
than one published value29,35.
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Here, we objectively assess pharmacological and clinical differences between the four FDA-approved PARP 
inhibitors, olaparib, rucaparib, niraparib and talazoparib. We use a combination of computational and experi-
mental methods to comprehensively dissect the kinome-wide off target landscape of these PARP inhibitors. We 
also perform a meta-analysis of FDA approval and key clinical trial data to map the clinically observed adverse 
effects and hypothesise potential links to the polypharmacology.
Results
In silico target profiling predicts new kinase off-targets of clinical PARP inhibitors. We applied 
three parallel computational methods to predict off-targets: (1) a consensus of six ligand-based chemoinformatic 
methods integrated in the Chemotargets CLARITY platform34; (2) the Similarity Ensemble Approach (SEA)7; 
and (3) the multinomial Naive Bayesian multi-category scikit-learn method implemented in ChEMBL35. The 
common principle for these methods is that chemically similar molecules should share similar bioactivity pro-
files against molecular targets; however, the details of the methods, including the computational representation 
(fingerprints) of compounds and similarity calculations used, are distinct. We employed these three computa-
tional methods to predict the kinase off-targets of the four FDA-approved PARP inhibitors, olaparib, rucaparib, 
niraparib and talazoparib. In addition to recovering most of the known interactions with members of the PARP 
family, the three in silico methods predicted a total of 58 potential interactions between PARP inhibitors and 
kinases, with only 10 of them being previously known30 (Table 2, Supplementary Tables 2–4).
CLARITY predicted 23 kinases as potential off-targets of olaparib (Supplementary Table 2). However, neither 
ChEMBL nor SEA predicted any kinase for this PARP drug (Supplementary Tables 3–4). A close inspection of 
the CLARITY predictions revealed that they were all generated from the similarity of olaparib to a single kinase 
inhibitor that was likely to be a false positive due to the absence within its structure of a benzamide moiety, which 
is known to be important for PARP binding (Supplementary Table 2)15.
CLARITY predicted seven kinases as potential off-targets of niraparib while ChEMBL predicted three kinases 
and the SEA method predicted one kinase (Table 2, Supplementary Tables 2–4). However, while all the meth-
ods predicted kinases as potential off-targets for niraparib, no two methods predicted the same kinase. The lack 
of agreement between the methods indicates that niraparib may have general kinase-binding features rather 
than specific molecular features associated with defined kinases. Interestingly, the only known kinase off-target 
of niraparib reported previously in the literature had low affinity (DCK IC50 = 67.9 μM)33. In addition, some 
of the kinase inhibitors that are identified as similar to niraparib exhibit PARP-binding features. For example, 
CHEMBL2035040, a weak AKT inhibitor, shares the key benzamide moiety with niraparib and other PARP 
inhibitors.
We have previously demonstrated that rucaparib inhibits nine kinases with micromolar potency30. Given the 
high degree of polypharmacology of many kinase inhibitors, we hypothesized that rucaparib could inhibit more 
kinases than the ones already identified. None of the three computational methods used here predicted all of the 
nine kinase off-targets that are already known. CLARITY, ChEMBL and SEA correctly predicted four, two and 
four known kinase off-targets, respectively, for rucaparib. Additionally, CLARITY predicted three new kinases, 
and ChEMBL predicted nine new kinase off-targets (Table 2, Supplementary Tables 2–4). Overall, twelve new 
kinase off-targets in total were predicted for rucaparib.
Finally, CLARITY and ChEMBL predicted only one kinase off-target each for talazoparib whilst SEA pre-
dicted none (Table 2). This low number of kinase off-target predictions suggests that it is less likely that talazo-
parib inhibits kinases (Supplementary Tables 2–4).
Overall, the lack of consensus on specific kinase off-targets between the three computational methods 
(Table 2, Supplementary Tables 2–4) is noteworthy and indicates a need for improvement, especially given the 
PARP 
inhibitor
Year of 
approval Indication and expanded indication
Olaparib
2014
Treatment of patients with deleterious or suspected deleterious germline BRCA mutated 
(gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of 
chemotherapy.
2017
Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, 
or primary peritoneal cancer, who are in a complete or partial response to platinum-based 
chemotherapy.
2018
Treatment of patients with deleterious or suspected deleterious germline BRCA-mutated 
(gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy 
either in the neoadjuvant, adjuvant, or metastatic setting.
Rucaparib
2016
Treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated 
epithelial ovarian, fallopian tube or primary peritoneal cancer who have been treated with two 
or more chemotherapies.
2018 Maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Niraparib 2017
Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, 
or primary peritoneal cancer who are in complete or partial response to platinum-based 
chemotherapy.
Talazoparib 2018 Treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer.
Table 1. Evolution of the indications for FDA-approved PARP inhibitors. Data were extracted from the FDA 
Hematology/Oncology (Cancer) Approvals & Safety Notifications (accession date 29th May 2018)65.
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expanding use of these computational approaches36. It is particularly puzzling given that all three methods are 
based on chemical structure similarity and use the same underlying medicinal chemistry databases – highlight-
ing the sensitivity of such predictions to the specific computational representation of compounds and statistics 
utilised. Based on our experience, we advise that, until these methodologies improve, researchers should apply as 
many predictive computational methods as possible. However, despite the differences in the detail, an important 
message is that all three methods did predict a range of kinases as potential off-targets of niraparib and rucaparib, 
thus increasing the confidence in our hypothesis that additional kinase off-targets are likely to be found for PARP 
drugs (Table 2).
Kinome profiling with a binding assay uncovers differential polypharmacology between clinical 
pARp inhibitors. To follow up the computational analysis, we performed a comprehensive in vitro kinome 
screen. To do this we employed the DiscoveRx (https://www.discoverx.com) KinomeScan in vitro binding tech-
nology37,38 that has been widely used for kinome profiling in drug discovery. At the time of conducting our screen, 
this kinome panel was the largest commercially available and comprised 468 in vitro binding assays correspond-
ing to 392 unique human kinases (76% of the human kinome)39 (Supplementary Table 5). Also included were 
assays comprising mutated, deleted, phosphorylated or autoinhibited forms of proteins (n = 63), secondary or 
pseudokinase domains (n = 8), non-human isoforms (n = 3) and CDK complexes with different cyclins (n = 2) 
(Supplementary Table 5). The assays were performed at a single relatively high concentration of 10 μM to identify 
initially both low and high potency off-targets.
The results of our use of the in vitro binding assay for kinome profiling reveal marked differences between 
the kinase polypharmacology of PARP inhibitors. As illustrated in Fig. 2, rucaparib and niraparib bind to many 
kinases while talazoparib binds only weakly to two kinases and olaparib does not bind to any of the 392 kinases 
tested (Supplementary Table 5). The binding technology used involves a competition assay, defining activity as 
≥65% of the kinase being competed off an immobilised ligand at 10 μM38. Using this measure, rucaparib binds to 
37 kinases while niraparib binds to 23 kinases (Table 2, Supplementary Table 5). Moreover, there is only partial 
overlap between the measured kinase polypharmacology of niraparib and rucaparib, with both drugs binding to 
15 shared kinases. Interestingly, the two kinases to which talazoparib showed weak binding are CLK3 and MTOR, 
neither of which bind the more broadly acting rucaparib and niraparib.
Importantly, as illustrated in Fig. 2, the off-target kinase activities of the four PARP inhibitors do not cluster 
in one single kinase family but are fairly widely distributed across the kinome. When carried out at the 10 μM 
concentration used, the in vitro binding assay is able to recover most of the previously known off-targets of ruca-
parib, including the most potent known interactions with PIM1 and DYRK1A. However, the previously described 
weaker interactions of rucaparib with PRKD2, CDK9, PIM2 and ALK were not reproduced by the binding assay. 
A further two known off-targets, CDK1 and DCK, were not available in the kinome panel used.
Overall, our results provide empirical evidence that the polypharmacology profile is indeed different for the 
four different PARP inhibitors studied. Consistent with the prediction by the computational methods, rucaparib 
and niraparib demonstrate multiple kinase polypharmacology, with fewer or no off-targets for talazoparib and 
olaparib.
Orthogonal catalytic inhibition assay confirms DYRK1s, PIM3 and CDK16 as submicromolar 
off-targets of niraparib and rucaparib. Next, we decided to validate the observed activities in an orthog-
onal experimental method, namely direct inhibition of kinase catalytic activity using Reaction Biology’s HotSpot 
platform (http://www.reactionbiology.com)40. This platform employs a widely-used and validated radiometric 
assay which measures inhibition of the incorporation of radiolabelled phosphate into protein substrate41. Of the 
24 kinases showing the greatest binding by the PARP inhibitors (≥85% binding at 10 μM, Supplementary Table 5) 
four were not available for follow-up testing with the HotSpot platform (highlighted in Supplementary Table 5). 
Thus, in total we tested 20 kinases in the radiometric catalytic inhibition assay, initially at a 1 μM concentration of 
the PARP inhibitors (Table 3). Of these, four were inhibited more than 50% by rucaparib and/or niraparib, namely 
DYRK1B, CDK16/cyclin Y, PIM3 and DYRK1A (Table 3).
Some of the initial hits identified in the DiscoveRx KinomeScan binding assay – such as TSSK3 – could not 
be reproduced using the orthogonal radiometric catalytic assay. This is frequently observed when comparing 
binding and catalytic assays42, due to factors such as differences in assay methods and conditions (e.g. protein 
constructs and drug concentrations used). Interestingly, although the primary hits from the binding assay are 
widely distributed across the kinome tree (Fig. 2), the 20 selected kinases showing the greatest binding by the 
Method Class Method
Number of kinases affected
Olaparib Rucaparib Niraparib Talazoparib
Computational
CLARITY34 23* 7 7 1
ChEMBL35 0 11 3 1
SEA66 0 4 1 0
Experimental In vitro binding (KinomeSCAN®)38 0 37 23 2
Table 2. Comparison of the number of kinases predicted for clinical PARP inhibitors using three in silico 
target profiling methods and those experimentally observed by in vitro kinome binding at 10 μM. *Prediction 
originating from the similarity to a single kinase inhibitor that is likely a false positive.
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PARP inhibitors are from only 5 different kinase groups and the submicromolar kinase off-targets of PARP inhib-
itors in the radiometric catalytic assay are all from the CMGC and CAMK groups (Table 3). At the submicromolar 
level tested in the catalytic assay (>50% inhibition at 1 μM), rucaparib inhibited kinases from both groups but 
niraparib inhibited only two kinases from the CMGC group. DYRK1B was the only kinase inhibited by both ruca-
parib and niraparib at concentrations below 1 μM (Table 3). These results further emphasize the different kinase 
polypharmacology behaviour exhibited between these two clinical PARP inhibitors.
Given our identification of potent new submicromolar off-targets that could have clinical implications, we 
determined the IC50 values for kinases showing >50% inhibition at 1 μM using Reaction Biology’s radiometric 
10-point concentration-response catalytic inhibition assay (Fig. 3, Supplementary Table 6). Rucaparib inhibits the 
activity of three kinases (CDK16, PIM3 and DYRK1B) with submicromolar IC50 values, the most potent being 
CDK16 (IC50 = 381 nM). In contrast, niraparib inhibits the activity of only two kinases with submicromolar IC50 
values, the most potent being DYRK1B (IC50 = 254 nM). To our knowledge, this is the first report of submicro-
molar non-PARP family off-targets of PARP inhibitors.
Our docking analysis (see Methods and Supplementary Figs. 1, 2) suggests limited similarity in key contacts 
between the drugs and their most significant kinase off-targets. All our tested PARP inhibitors, with their varying 
activities, contain the benzamide moiety which is a key feature for PARP binding. This, together with the lack 
of predicted common contacts demonstrates that it is unlikely that the benzamide moiety is a major contributor 
Figure 2. Kinome profiling of the four FDA-approved PARP inhibitors across 392 unique human kinases and 
76 mutated, atypical and other forms. This was carried out using the in vitro binding platform of DiscoveRx’s 
KinomeScan®38. The assays were perfomed at a single 10 μM concentration. The TREEspot™64 representations 
of the kinome tree, with superimposed in vitro binding data for each PARP inhibitor, illustrate how rucaparib 
and niraparib bind to a significant number of kinases while talazoparib only modestly binds to two kinases and 
olaparib does not bind to any of the kinases tested. The chemical structures of the PARP drugs are included 
and their different R-groups highlighted in blue shading to illustrate different side-chains that may influence 
polypharmacology.
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to kinase binding30. It is possible that the flatter shape of niraparib and rucaparib might allow a better fit in the 
kinase binding sites as compared to the bulkier talazoparib and the more flexible olaparib. In turn, this might be 
responsible for their better docking scores and affinities for kinases. Experimental validation of the predicted 
binding is required to test these hypotheses.
Intracellular target engagement confirms submicromolar binding to CDK16 and DYRK1A in 
transfected HEK293 cells. To test whether the observed biochemical activity translated to cellular activity, 
we performed intracellular target engagement assays for selected kinases using Reaction Biology’s NanoBRET 
platform (http://www.reactionbiology.com). From the most potent submicromolar off-targets identified in the 
biochemical radiometric catalytic assay (Fig. 3), only CDK16 and DYRK1A were available on the NanoBRET 
platform. We tested rucaparib against CDK16 and niraparib against DYRK1A. We also included olaparib as a 
negative control. Importantly, the results demonstrate intracellular concentration-responsive binding of both 
CDK16 by rucaparib and DYRK1A by niraparib in this live cell system (Supplementary Table 7). The EC50 val-
ues for both interactions are in the 200–230 nM range (niraparib DYRK1A EC50 = 209 nM; rucaparib CDK16 
EC50 = 223 nM). As expected, olaparib does not modulate either of the tested off-target kinases (Fig. 3). Overall, 
these results further support the off-target inhibition of kinases by some PARP inhibitors at clinically achievable 
concentrations and in particular reveal kinase engagement in live cells in the submicromolar range.
Meta-analysis of clinical response and side-effects between PARP inhibitors. Rucaparib and 
niraparib received FDA-approval in 2016 and 2017 for a recommended dose of 600 mg taken twice daily and 
300 mg taken once daily, respectively (Table 1)17,18. At these clinical doses, their steady-state Cmax concentrations 
in plasma range between 2–9 μM for rucaparib43 and 3–4 μM for niraparib44. These micromolar Cmax concen-
trations are well above the submicromolar in vitro IC50 concentrations for their most potent kinase off-targets.
There are no clinical trials comparing PARP inhibitors directly side by side. Registration trials in ovarian 
cancers for each of the drugs have also been carried out on genetically different population groups. Nonetheless, 
progression-free survival (PFS) achieved by the intervention arms versus placebo were largely similar for olap-
arib, rucaparib and niraparib (Hazard ratios (HR) of 0.30, 0.36 and 0.26, respectively). Talazoparib seems to 
provide the shortest PFS (8.6 months). However, talazoparib was compared to standard of care chemotherapy, 
achieving an HR of 0.54. In summary, based on existing clinical efficacy data it is difficult to distinguish between 
the alternative inhibitors (Table 4).
To assess adverse reactions, we first used the FDA prescribing information16–18 to analyse all 61 reported 
adverse events and laboratory abnormalities for the four FDA-approved PARP inhibitors (Supplementary 
Kinase Group Gene Name Kinase complex and aliases Niraparib Rucaparib
CMGC DYRK1B — 82% 53%
CMGC CDK16 CDK16/cyclin Y (PCTAIRE, PCTK1) n.b. 82%
CAMK PIM3 — 15% 78%
CMGC DYRK1A DYRK1 76% 49%
CMGC HIPK1 — 40% −16%
CAMK MYLK4 — 19% 36%
Other AURKB Aurora B 34% n.b.
CMGC HIPK2 — 23% −6%
CAMK PIM1 — 22% 27%*
CMGC CSNK2A1 CK2a 12% 21%
AGC LATS2 — 17% n.b.
CMGC CSNK2A2 CK2a2 −1% 17%
AGC CIT STK21 10% 15%
Other HASPIN Haspin 10% −6%
CMGC CDK4 CDK4/cyclin D3 n.b. 10%
CMGC HIPK3 — 5% −12%
CAMK TSSK3 STK22C n.b. −1%
PKL PIK3C3 VPS34 −1%* n.b.
CAMK PIM2 — −5% n.b.
CAMK STK17A DRAK1 n.d. −6%
Table 3. Validation of the most potent interactions identified in the in vitro binding assay at 10 μM (see 
Methods, Fig. 2, Supplementary Table 5) using an orthogonal assay that directly measures kinase catalytic 
activity using a widely-validated radiometric assay40. The table displays the average of duplicate (n = 2) 
measurements of the percentage of enzyme inhibition relative to DMSO controls sorted by maximum 
percentage of inhibition. All assays were performed using 1 μM drug concentration and the appropriate Km 
concentration of ATP. From all the tested kinases, only 4 inhibit the enzyme by >50%. These four most potent 
interactions, expected to be submicromolar, are displayed at the top of the table and in bold. n.b. not binding. 
n.d. not determined due to low binding (Supplementary Table 5). * n = 1.
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Table 8). Given the lack of direct, quantitative, comparative studies, we summarised the findings into qualitative 
categories to allow comparison (Supplementary Table 9). Next, we abstracted the reported adverse reactions in 
the four largest clinical trials of olaparib45, rucaparib46, niraparib47 and talazoparib48. Despite obvious limitations 
in comparing different trials, the combination of the abstracted information provides high-level insights into sim-
ilarities and differences between the different PARP inhibitor side-effects (detailed in Supplementary Tables 8, 9).
Of the 61 analysed parameters, 21 are shared between all four approved PARP inhibitors although some are 
only rarely observed. These include frequently observed side-effects of cancer therapeutics such as nausea, vomit-
ing or diarrhoea. Of the 61 parameters, 40 were reported to be commonly observed side-effects for at least one of 
the four drugs (Supplementary Table 9). Several of these effects are shared between most PARP drugs, such as the 
Figure 3. Concentration-response curves for the most potent kinase off-target interactions of clinical PARP 
inhibitors. (a) concentration-response curves and IC50 calculation of the most potent interactions in the in vitro 
binding assay (see Methods) of niraparib (top) and rucaparib (bottom) analysed in triplicate using Reaction 
Biology’s HotSpot radiometric assay that directly measures kinase catalytic activity40. (b) concentration-
response curve and EC50 calculation for rucaparib against CDK16 and niraparib against DYRK1A using a 
target-engagement cellular assay based on NanoBRET technology and an optimized set of cell-permeable kinase 
tracers (see Methods for details). Olaparib was used as a negative control. The target engagement cellular assays 
were performed in quadruplicate (two technical repeats in each of two independent experiments). (c) table 
summarising the calculated IC50 and EC50 values for the kinase off-targets DYRK1B, CDK16, PIM3 and DYRK1A.
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increase in serum creatinine, which is reported during treatment with olaparib, rucaparib and niraparib but not 
talazoparib (Fig. 4). Other side-effects, such as palpitations, are reported only for two clinical PARP inhibitors. 
Finally, all four drugs have unique commonly observed side-effects not shared with other PARP inhibitors. For 
example, rucaparib is the only PARP inhibitor reported to increase cholesterol and talazoparib is the only PARP 
inhibitor reported to produce alopecia (Fig. 4). All the nineteen distinct side-effects are commonly observed for 
their respective drugs (as reported in the Prescribing Information). Overall, FDA-approved PARP drugs appear 
to have distinct side-effect profiles and we hypothesize that their unique polypharmacological profiles could 
contribute to them.
Discussion
In this study, we perform a comprehensive computational analysis and experimental characterization of the 
off-target kinase landscape of the four clinical PARP inhibitors that are currently approved. We demonstrate 
that each PARP inhibitor has a unique off-target profile across the kinome that should be considered for both the 
clinical development of PARP inhibitors and the design of new PARP inhibitors with desired polypharmacology. 
We uncover previously unreported kinase off-targets for the FDA-approved PARP drugs niraparib and rucaparib 
which we experimentally confirm for the first time to have submicromolar inhibitory activities (Figs. 2 and 3). 
Niraparib inhibits DYRK1A and DYRK1B whilst rucaparib inhibits CDK16, PIM3 and DYRK1B – all with sub-
micromolar potencies (Fig. 3). We also demonstrate submicromolar intracellular target engagement in live cells 
for rucaparib binding to CDK16 and niraparib binding to DYRK1A (Fig. 3). We propose that the inhibition by 
rucaparib and niraparib of DYRK1A/B, CDK16 and PIM3, among other kinases, may have potential clinical 
relevance and thus warrant further investigation. Moreover, our findings highlight the importance of considering 
kinase off-targets in the future discovery and development of PARP inhibitors.
Our results illustrate the challenge of comprehensively uncovering drug polypharmacology. We find limi-
tations in all screening assay formats, including chemical proteomics. While computational target prediction 
methods are increasing in sophistication, we show that they learn general patterns rather than specific details. For 
example, although all computational methods used here predicted kinases as potential off-targets of PARP inhib-
itors, the methods showed little overlap in terms of either the precise computational predictions or the results of 
the experimental measurements (Supplementary Tables 2–6). It is important to note that currently available bio-
activity data in public databases are strongly biased towards commonly studied targets, including many kinases. 
This bias may well contribute to the strong computational prediction of kinase polypharmacology that we observe 
in the current study. Increasing the target coverage of the public databases will improve the training of computa-
tional models. Moreover, current public pharmacological databases focus on the medicinal chemistry literature 
and data published in journals outside that domain are often missing. For example, the pharmacological data 
for the previously known kinase off-targets of rucaparib are not available in public databases such as ChEMBL35 
as they were published in a specialized cancer journal rather than a medicinal chemistry journal30. This is an 
important limitation for the training of computational models. In the present work, we observe that none of the 
computational methods used is able to recover all the known off-targets of rucaparib because they could not use 
the above-mentioned profiling data for model building. It is therefore essential that we increase the coverage of 
public databases to include pharmacological data published outside the medicinal chemistry literature, in order 
to improve computational methods. Meanwhile, users of such computational methods are advised to apply as 
Drug Registration trial,
Cohort description & 
size
Median PFS
(Intervention vs 
Control) HR 95%CI P-value
Olaparib
SOLO-1 (NCT01844986) 
https://www.nejm.
org/doi/full/10.1056/
NEJMoa1810858
BRCA mutant 
Olaparib = 260 
Placebo = 131
Not reached vs 
13.8mo 0.30 0.23–0.41 <0.0001
Rucaparib
ARIEL3 (NCT01968213) 
https://www.thelancet.
com/journals/lancet/
article/PIIS0140–
6736(17)32440–6/fulltext
Total cohort 
Rucaparib = 375 
Placebo = 189
10.8mo vs 5.4mo 0.36 0.30–0.45 <0.0001
BRCA mutant 
Rucaparib = 130 
Placebo = 66
16.6mo vs 5.4mo 0.23 0·16–0·34 <0·0001
Homologous 
Recombination-deficient 
Rucaparib = 236 
Placebo = 118
13.6mo vs 5.4mo 0·32 0·24–0·42 <0·0001
Niraparib
NOVA (NCT01847274) 
https://www.nejm.
org/doi/full/10.1056/
NEJMoa1611310
BRCA mutant 
Intervention = 138 
placebo = 65
21mo vs 5.5mo 0.26 0.17–0.41 <0.0001
Talazoparib
EMBRACA 
(NCT01945775) 
https://www.nejm.
org/doi/full/10.1056/
NEJMoa1802905
BRCA mutant & HER2-
negative Talazoparib = 287 
SoC = 144
8.6mo vs 5.6mo 0.54 0.41–0.71 <0.0001
Table 4. Clinically observed progression-free survival data for the registration trials of the four FDA approved 
PARP inhibitors in ovarian and breast cancer.
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many approaches as possible in order to seek a wide range of predictions, and in addition are advised to rely only 
on those that are experimentally validated.
The availability of experimental in vitro biochemical target profiling panels at relatively low cost through con-
tract research organisations (CROs) is strongly enabling – especially democratising off-target identification and 
validation for smaller enterprises and academic groups. However, technological differences between platforms, 
including protein expression constructs and systems, purification procedures and assay conditions, affect the 
results found42. In the present study, most of the already known off-targets of PARP inhibitors were reproduced 
by the in vitro competitive binding platform that we used for initial experimental profiling. However, in line with 
previous observations42, some of the strongest binding signals observed with this assay at a compound concen-
tration of 10 µM were not reproduced using a complementary, well-established radiometric catalytic inhibition 
assay. Moreover, although increasing in coverage, current screening panels are not yet fully comprehensive – 
even across widely-studied target families such as kinases49. Finally, the results of a recent chemical proteomics 
analysis of the selectivity of clinical PARP inhibitors failed to identify the targets that we discovered and exper-
imentally confirmed – although of course the chemical proteomics technology is able to sample the proteome 
more broadly33. There are several factors limiting the use of chemical proteomics in this setting, such as the level 
of expression of proteins in the cells used and the unknown full effects of the attached tags across the proteome.
Overall, our results illustrate the complementarity between different methods in addressing the challenging 
task of systematically uncovering the molecular target profile of drugs to further our understanding of polyphar-
macology and its potential impact for efficacy and safety in the clinic.
The clinical PARP inhibitors exhibit different sensitivity across cancer cell lines when measured in large-scale 
screens, enabling the prediction of distinct genomic biomarkers of drug sensitivity (Supplementary Table 1)27. It 
is possible that differential effects between cancer cell lines may relate to the different polypharmacology of PARP 
inhibitors. We demonstrate intracellular target engagement of CDK16 by rucaparib and DYRK1A by niraparib 
with EC50 values in the 200–230 nM range in live transfected HEK293 cells (Fig. 3). Moreover, the unique capac-
ity of rucaparib to inhibit STAT3 phosphorylation in MDA-MD-231 and MDA-MB-468 human breast cancer 
cell lines has been previously reported at concentrations below 2.5 μM, but this was not observed in response 
Figure 4. The nineteen differential adverse reactions between FDA-approved clinical PARP inhibitors. Data 
were extracted from the FDA prescribing information and published results of the largest clinical trials. Side-
effect frequencies are not considered due to the differences between the cut-offs used in each trial and FDA 
prescribing information for each PARP inhibitor (see Methods for details). Each adverse reaction considered 
common for at least one PARP drug and not identified for at least another PARP inhibitor is represented as a 
circle. The circles are coloured according to the drugs that present this adverse reaction in their prescribing 
information or publication of their largest clinical trial.
1 0Scientific RepoRtS |         (2020) 10:2585  | https://doi.org/10.1038/s41598-020-59074-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
to olaparib25. PIM3 is known to phosphorylate STAT350 and we show that rucaparib is the only FDA-approved 
PARP inhibitor that inhibits PIM3. These results further support the relevance the kinase polypharmacology of 
PARP inhibitors in a cellular context. Both the observed differential cellular effects and the differential polyphar-
macology necessitate consideration of more system-wide effects of PARP inhibitors and their kinase off-targets, 
particularly in organs that are exposed to high drug concentrations, such as the blood and the liver. Indeed both 
DYRK1A and CDK16 proteins are highly expressed in the bone marrow, immune cells and the liver while CDK16 
is very broadly expressed51.
We have demonstrated that rucaparib and niraparib bind their intracellular kinase off-targets at submicromo-
lar concentrations in live cells. However, as shown in Fig. 1, all examined PARP inhibitors have low nanomolar 
potencies against their PARP targets whereas the potencies against kinases are in the 200 nM to low micromolar 
range. Moreover, drug penetration inside solid tumours is frequently limited52. Therefore, these off-target activ-
ities are unlikely to compete directly anti-PARP activity at the tumour site. Yet, the micromolar clinical concen-
trations achieved, especially at sites of higher drug concentrations including the blood and the liver, may have 
potential clinical implications with respect to efficacy in haematological cancers and with respect to observed 
adverse-effects.
Analysing the expression of potent kinase off-targets of PARP inhibitors in haematological cancers using can-
SAR53 reveals that DYRK1A and DYRK1B are overexpressed at the mRNA level in several types of leukaemia and 
lymphoma (Supplementary Figs. 3–6). Interestingly, DYRK1A has been associated with acute lymphoblastic leu-
kaemia (ALL) in children with Down syndrome (DS), because it is located on chromosome 21 and overexpressed 
as part of the trisomy that characterizes this disease54. Given the high micromolar concentration that niraparib 
can reach in the blood, this PARP inhibitor could be investigated as a potential repurposing opportunity for this 
rare paediatric leukaemia54.
Our meta-analysis of FDA and clinic-reported adverse events shows that each PARP drug has a unique clin-
ical adverse side-effect pattern and we hypothesize that this may potentially relate, at least in part, to the unique 
kinase off-target profile (Fig. 4, Supplementary Tables 8, 9). Since adverse side-effects could result through a 
multitude of mechanisms, it is not possible to ascribe each side-effect to specific kinase off-targets. Nevertheless, 
the unique inhibition of PIM3 by rucaparib and not by olaparib, niraparib or talazoparib suggests the hypothesis 
that it may potentially contribute to the unique elevations in cholesterol that are observed in patients treated 
with rucaparib but not the other three PARP inhibitors (Fig. 3). Interestingly, PIM3 has been recently found to 
be regulated downstream of mTORC1 by miR-33 – encoded by the SREBP loci55. SREBP and miR-33 are known 
regulators of cholesterol homeostasis56. Moreover, transgenic mice overexpressing PIM3 in the liver showed an 
increase of lipid droplet accumulation57 while PIM1 is known to stabilize the cholesterol transporter55 and there 
is substantial functional redundancy in the PIM kinase family. Accordingly, the high drug concentrations that the 
liver is exposed to and the unique inhibition of PIM3 by rucaparib (Fig. 3) are consistent with the hypothesis that 
PIM3 kinase inhibition may potentially be responsible for this differential side-effect (Fig. 4). However, further 
experimental and clinical validation is needed to test this hypothesis, for example by comparing biomarkers of 
PIM3 response in patients treated with different PARP inhibitors.
The distinct kinase off-target and adverse side-effect profiles between PARP inhibitors that we have identified 
caution against the assumption that PARP inhibitors are clinically equivalent in all disease and treatment sce-
narios. Moreover, any differences could be magnified when PARP inhibitors are used in combination with other 
drugs that could synergise differently with the different kinase off-target activities of clinical PARP inhibitors. This 
might be particularly important in drug combinations with immunotherapy due to the likely higher concentra-
tions of PARP inhibitors in the blood compared to the tumour site. Currently, there are at least 30 clinical trials 
studying combinations between PARP inhibitors and immunotherapies (Supplementary Table 10) but none is 
comparing any PARP inhibitors side by side.
The submicromolar kinase activities that we identify for PARP inhibitors here could potentially have an 
impact on the complex interplay between PARP inhibitors and immunotherapeutics. For example, the niraparib 
off-target DYRK1A is known to regulate the branching point between Th17 and Treg differentiation58. Therefore, 
DYRK1A may potentially play a role in increasing the Treg cell population that in turn may antagonise the effects 
in PARP-immunotherapy drug combinations58,59. If this is the case, the combination of olaparib or niraparib with 
immunotherapy drugs may give different results and we recommend that this should be investigated carefully. 
More generally, it is possible that some of the potent kinase off-targets of PARP inhibitors reported in this study 
could modulate T cell homeostasis and the potential implications should be validated further to maximize PARP 
drug combinations with immunotherapy.
conclusions
In summary, our comprehensive computational and experimental analysis demonstrates that PARP inhibitors 
have an inherent capacity to inhibit kinases off-target and illustrates that each of the clinically approved PARP 
inhibitors investigated in this work has a unique polypharmacological kinase profile. Our findings emphasize the 
importance of comprehensive kinase profiling, using orthogonal technologies, of all candidate PARP inhibitors 
and in addition opens up potential new avenues for the rational design of dual PARP-kinase inhibitors with tar-
geted polypharmacology. Of particular note, we identify novel submicromolar off-target kinases for rucaparib 
and niraparib. In addition, we demonstrate through our analysis of prescribing information and key clinical 
trials that FDA-approved PARP drugs have distinct clinical side-effect profiles and we recommend that studies be 
undertaken to determine the potential contribution of off-target kinase effects to those side-effects. Moreover, we 
propose that studies be undertaken to explore the potential repurposing of niraparib in paediatric acute lymph-
oblastic leukemia that occurrs in children with Down syndrome. In addition, our study highlights the field’s cur-
rently limited understanding of drug polypharmacology and its implications for efficacy and safety in the clinic. 
This is particularly important when considering drug combinations, including those involving immunotherapy, 
1 1Scientific RepoRtS |         (2020) 10:2585  | https://doi.org/10.1038/s41598-020-59074-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
with limited understanding of the polypharmacological liabilities of the combined drugs. However, through the 
application of complementary technologies, we can – as we show here – map key polypharmacological profiles 
and generate testable hypotheses with clinical potential. In this way, we can help facilitate the maximal exploita-
tion of PARP inhibitors and other drugs for patient benefit.
Methods
Drug acquisition. All compounds were purchased from Selleckchem.com
In silico target profiling. Three computational methods based on chemical similarity were used to predict 
the kinase off-targets of clinical PARP inhibitors. The canonical SMILES used to define the chemical structures of 
the four clinical PARP inhibitors analysed were obtained from ChEMBL35. The first method used was the prede-
fined consensus of six ligand-based chemoinformatic methods available in the Chemotargets CLARITY platform 
(https://www.chemotargets.com) and a predefined panel including PARPs and kinases was selected for off-target 
prediction34. Secondly, we used the Similarity Ensemble Approach (SEA) method (http://sea.bkslab.org/) set 
to default parameters7. The third method used was the multinomial Naive Bayesian multi-category scikit-learn 
similarity-based method implemented in ChEMBL that can be accessed from the ChEMBL website (https://
www.ebi.ac.uk/chembl/)35. The raw data from the predictions we obtained can be accessed in Supplementary 
Tables 2–4.
In vitro kinome profiling measuring drug binding. The DiscoveRx KinomeScan platform (https://www.
discoverx.com), utilizing an in vitro active site-directed competition binding assay, was used to quantitatively 
measure interactions between the four clinical PARP inhibitors and their largest available kinase panel. At the 
time when the assays were performed (date: 29/11/2016), 468 in vitro binding assays were available, correspond-
ing to 392 unique human kinases (76% of the human kinome)39 (Supplementary Table 5).
In vitro kinase radiometric assays. Reaction Biology’s HotSpot platform (http://www.reactionbiology.
com)40, which employs a radiometric assay to measure phosphorylation of substrate, was used to validate the hits 
from the kinome binding assay. The radiometric assay is designed to directly detect the true product without the 
use of modified substrates, coupling enzymes, or detection antibodies. Test or control compounds are incubated 
with kinase, substrate, cofactors, and radioisotope-labelled ATP (33P-ɣ-ATP). The reaction mixtures are then 
spotted onto filter papers, which bind the radioisotope-labelled catalytic product, for subsequent measurement. 
Unreacted phosphate is removed via washing the filters41.
intracellular target engagement kinase assays. Reaction Biology’s NanoBRET platform (http://www.
reactionbiology.com)60,61 employs a biophysical technique that enables the quantitative determination of kinase 
inhibitor occupancy by a ligand in intact living cells. This live cell quantitative capability is achieved via BRET 
with an optimized set of cell-permeable kinase tracers. The specificity of the BRET signal is dictated by the place-
ment of NanoLuc on the chosen kinase target and transfected into HEK293 cells. These assays were performed 
at Reaction Biology.
HEK293 human embryonic kidney cells were from ATCC. FuGENER HD Transfection Reagent, 
KinaseNanoLuc® fusion plasmids, Transfection Carrier DNA, NanoBRET™ Tracer and dilution buffer, 
NanoBRET™ Nano-Glo® Substrate, Extracellular NanoLuc® Inhibitor were from Promega. Olaparib was always 
used as a negative control and APY-69 and CEP701 were used as positive controls for the CDK16 and DYRK1A 
assays, respectively.
HEK293 Cells were transiently transfected with KinaseNanoLuc® Fusion Vector DNA by FuGENER HD 
Transfection Reagent. Test compounds were delivered into 384 well assay plate using an Echo 550 acoustic dis-
penser (Labcyte Inc, Sunnyvale, CA). Transfected cells were harvested and mixed with NanoBRET™ Tracer 
Reagent and dispensed into 384 well plates and incubated the plates at 37 °C in 5% CO2 cell culture incubator 
for 1 hour. The NanoBRET™ Nano-Glo® Substrate plus Extracellular NanoLuc® Inhibitor Solution were added 
into the wells of the assay plate and incubated for 2–3 minutes at room temperature. The donor emission wave-
length (460 nm) and acceptor emission wavelength (600 nm) were measured in an EnVision plate reader. The 
BRET Ratio were calculated using the equation: BRET Ratio = [(Acceptor sample ÷ Donor sample) – (Acceptor 
no-tracer control ÷ Donor no-tracer control)].
Docking experiments. Of the four protein kinases inhibited with submicromolar affinities by rucaparib 
or niraparib (Fig. 3), only DYRK1A and CDK16 had a 3D structure deposited in the PDB62. We selected the 
crystal structures of DYRK1A (PDB ID: 4AZE) and CDK16 (PDB ID: 3MTL) because they were the only ones 
co-crystallized with a ligand presenting a cyclic benzamide that mirrors the one present in all PARP inhibitors 
(Supplementary Table 11). The PDB files were prepared using the standard preparation method implemented 
in GOLD v5.6 (https://www.ccdc.cam.ac.uk/solutions/csd-discovery/components/gold/). The binding site was 
described by selecting residues at a distance of 6 Å from the co-crystallized ligand. The ligand structures were 
extracted from the PDB and edited to define the correct atom types. Docking was performed using standard 
variables for high conformation sampling (30 GA runs) and amide bond and ring system flexibility of the ligand 
were enabled. In order to facilitate the analysis of the molecular interactions between PARP inhibitors and 
kinase proteins in the best GOLD scoring poses, we used LigPlot + to generate 2D schematic diagrams of these 
protein-ligand interactions63.
Adverse side-effect analysis. FDA prescribing information was downloaded from the FDA website (www.
accessdata.fda.gov; accessed: 24/10/2018). The raw data describing the side-effects and laboratory abnormalities 
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and their frequencies were extracted from the FDA prescribing information documents (Supplementary Table 9). 
A total of 64 side-effects and laboratory abnormalities were described for the four FDA-approved PARP drugs 
(Supplementary Table 9). From the 64 side-effects, ‘decrease in leucocytes’ and ‘leukopenia’ were considered 
redundant side-effects and therefore were merged. Similarly, ‘nasopharyngitis/URI/sinusitis/rhinitis/influenza’ 
and ‘(upper) respiratory tract infection’ were also considered analogous and merged. Finally, ‘ALT increase’ and 
‘AST increase’ were also merged in a single side-effect. Accordingly, the final number of side-effects and labora-
tory abnormalities considered was 61 (Supplementary Table 10). The information was subsequently transformed 
into a binary format (1 = side-effect present; 0 = side-effect absent) (Supplementary Table 10). Uncommon 
side-effects by the definition of the FDA label were distinguished from common ones in two different columns 
(Supplementary Table 10). Differential side-effects were then compared to larger published clinical trials of olap-
arib, rucaparib and niraparib to make sure they were not observed in more recent and larger clinical trials that 
may not have been included in the labels45–47. Several of the differential side-effects initially identified in the FDA 
labels were indeed found to have been reported in larger clinical trials, such as dyspepsia, headache or myal-
gia that had been reported for rucaparib in the latest clinical trial despite not being included in the FDA label 
(Supplementary Table 9, 10)46. Figure. 4 summarizes the nineteen side-effects that are different between PARP 
inhibitors and that were also reported as common for at least one PARP inhibitor.
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